Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18
Rhea-AI Summary
Intelligent Bio Solutions (Nasdaq: INBS) announced management will participate in the Planet MicroCap Conference from June 16-18, 2026 at the Bellagio Hotel & Casino in Las Vegas.
The company will present on June 17, 2026, at 8:00–8:30 AM PDT in Track 7 – Donatello 3 and hold one-on-one investor meetings.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
INBS was down 3.94% with low volume while only one peer (XAIR) appeared in momentum scans, down ~4.9%. Broader peers were mixed: AIMD, NXL, NVNO down, but ALUR and SINT up double digits, pointing to stock-specific rather than sector-wide pressure.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | Clinical study launch | Positive | +2.4% | Started multi-site Method Comparison Study supporting FDA 510(k) submission for codeine. |
| May 13 | Earnings growth update | Positive | +25.5% | Reported Q3 2026 revenue up 46% with improved gross margin and cash balance. |
| Apr 20 | Validation study start | Positive | +10.2% | Initiated validation study targeting faster sub‑3‑minute drug screening results. |
| Apr 17 | Cybersecurity testing | Positive | -1.5% | Completed penetration testing with no major vulnerabilities, enhancing 510(k) readiness. |
| Apr 02 | Cut-off study complete | Positive | -11.9% | Completed initial clinical Cut-off Study and advanced 510(k) clinical program. |
Recent INBS news, especially clinical progress and earnings, has often led to positive moves, but there are notable instances where clinically positive updates saw negative reactions.
Over the last few months, INBS has reported multiple developments tied to its Intelligent Fingerprinting drug screening system and FDA 510(k) path. On Apr 2 and Apr 20, the company advanced clinical and validation studies, targeting faster sub‑3‑minute results and addressing a global TAM of $16.7B. An Apr 17 cybersecurity update and a Jun 2 multi-site Method Comparison Study further supported the 510(k) package. Earnings on May 13 highlighted 46% revenue growth and stronger margins. The current conference participation fits into ongoing investor outreach alongside this development trajectory.
Regulatory & Risk Context
An effective Form S-3 resale registration dated Jan 9, 2026 covers 6,896,550 shares issued in a December 31, 2025 private placement. INBS will not receive proceeds from resale, but could receive up to about $18.87 million if all underlying warrants are exercised for cash. The filing notes that the large registered resale block could pressure the stock price if sold rapidly and highlights ongoing Nasdaq listing risk.
Market Pulse Summary
This announcement details INBS’s participation at the Planet MicroCap conference from June 16–18, 2026, including a June 17 presentation and booth 413, underscoring active investor outreach. It follows recent clinical and regulatory progress toward FDA 510(k) submission and strong revenue growth of 46% year‑over‑year. Investors may monitor execution on the 510(k) timeline, continued revenue expansion, cash resources, and potential selling from the registered 6,896,550 resale shares under the existing shelf.
AI-generated analysis. Not financial advice.
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in the Planet MicroCap Conference on June 16-18, 2026, in Las Vegas, NV.
Conference Details
Date: June 16-18, 2026
Location: Bellagio Hotel & Casino, Las Vegas
Presentation Date and Time: Wednesday, June 17, 2026, at 8:00 – 8:30 AM PDT
Presentation Location: Track 7 – Donatello 3
Registration: Interested investors can register to attend here
Webcast: Viewable here
Booth: 413
The Company will be participating in one-on-one investor meetings throughout the event. For more information about the conference, or to schedule a meeting with the INBS management team, please contact your Planet MicroCap representative or email KCSA Strategic Communications at INBS@kcsa.com.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (Nasdaq: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
For more information, visit: https://ibs.inc/
Company Contact
Intelligent Bio Solutions Inc.
info@ibs.inc
Investor & Media Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
